We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Abbott Laboratories (NYSE ... This performance was particularly notable given the lower-than-expected Covid testing sales, which were offset by strong showings in other divisions.

On Wednesday, Abbott Laboratories (NYSE ... Organic growth, excluding COVID-19 testing-related sales was 10.1%. Adjusted diluted earnings per share were $1.34, in line with the analyst estimates ...

2025 Adjusted Tax Rate Forecast: 16% to 17%. Abbott Laboratories (NYSE:ABT) achieved a 9.5% sales growth excluding COVID testing, demonstrating strong performance across its business segments.

A high throughput, highly automated test system for blood screening ... and documenting for every run. ABBOTT PRISM is designed to increase lab efficiency. It reduces manual steps and checks ...

The outlook and technical action suggest Abbott Laboratories (NYSE ... in below consensus partly because of weakness in COVID-19 testing, but organic growth is double-digit, and all segments ...

AUSTIN, Texas — Austin’s Silicon Laboratories has received a $23.3 million grant from the Texas Semiconductor Innovation Fund (TSIF), Gov. Greg Abbott announced on Wednesday. The grant will help fund ...

Worldwide COVID-19 testing sales were $176 million in the ... 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%. Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05 ...

They are in a position to begin testing these molecules on human ... by 150 percentage points (see more details here). Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and ...